Results 191 to 200 of about 10,599,387 (354)

Hemolytic uremic syndrome post-diarrheal: (Week 44) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending November 4, 2023

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Hemolytic uremic syndrome post-diarrheal cases. The Weekly data are considered provisional and collected locally due to

core  

ANK1 and EPB41 Variants and the Risk of Steroid‐Induced Osteonecrosis

Arthritis &Rheumatology, EarlyView.
Objective Steroid‐induced osteonecrosis of the femoral head (SONFH) is a refractory skeletal disorder influenced by genetic and environmental factors. However, conclusive pathogenic genetic evidence remains elusive due to the limited exploration of rare damaging variants. In this study, we aimed to identify rare variants associated with SONFH.
Shengbao Chen, Xianmin Zhu, Zhongzhong Chen, Wei Chen, Hussam Alkaissi, Zeng Zhang, Yun Gao, Junhui Yin, Xiangtian Yu, Qiong Fu, Youshui Gao, Zhenzhong Zhu, Qianying Cai, Pengwei Zhang, Weibin Chen, Xin Zhao, Xiaojin Wu, Karel Pacak, Dongxu Jin, Chunde Bao, Zhengping Zhuang, Changqing Zhang   +21 more
wiley   +1 more source

Hemolytic Disease of the Fetus and Newborn in an Integrated Health Care System. [PDF]

Am J Perinatol
Fassett MJ, Khadka N, Xie F, Shi J, Chiu VY, Im TM, Kim S, Mensah NA, Park D, Mao C, Molaei M, Lin I, Getahun D.   +12 more
europepmc   +1 more source

Hemolytic uremic syndrome post-diarrheal: (Week 39) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending September 30, 2023

Hemolytic uremic syndrome post-diarrheal cases. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations.

core  

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. [PDF]

JMIR Res Protoc
Mensah NA, Fassett MJ, Khadka N, Shi JM, Xie F, Chiu VY, Im TM, Kim S, Park D, Mao C, Molaei M, Lin I, Getahun D.   +12 more
europepmc   +1 more source

Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease. [PDF]

Front Pediatr, 2023
Liu X, Dong Y, Qin Y, Xue C, Lyu W.
europepmc   +1 more source

Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn.

Hematology. American Society of Hematology. Education Program, 2015
M. Delaney, D. Matthews
semanticscholar   +1 more source

Hemolytic uremic syndrome post-diarrheal: (Week 41) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending October 14, 2023

Hemolytic uremic syndrome post-diarrheal cases. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations.

core  

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source